Literature DB >> 9001319

Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis.

K B Baumgartner1, J M Samet, C A Stidley, T V Colby, J A Waldron.   

Abstract

We conducted a multicenter case-control study of clinically and histologically diagnosed idiopathic pulmonary fibrosis (IPF), a chronic diffuse interstitial lung disease of unknown cause. The study included 248 cases, and 491 control subjects identified through random-digit dialing, matched to cases in sex, age, and geographic region. Telephone interviews were conducted with both cases and controls to collect information on potential risk factors for IPF, including smoking and household, occupational, and environmental exposures. Pulmonary function tests, X-rays, computed tomographic (CT) scans of the chest, and lung biopsy reports were submitted by referring centers to support the diagnoses. An a priori hypothesis that smoking is associated with IPF was examined with conditional logistic regression analyses. More cases (72%) than control subjects (63%) had a history of ever smoking. The odds ratio (OR) for ever smoking was 1.6 (95% CI: 1.1 to 2.4). Risk was significantly elevated for former smokers (OR = 1.9; 95% CI: 1.3 to 2.9) and for smokers with 21 to 40 pack-yr (OR = 2.3; 95% CI: 1.3 to 3.8). A history of smoking is associated with an increased risk for the development of IPF. Although there was no clear exposure-response pattern with cumulative consumption of cigarettes, there was a trend for time since cessation of smoking, with the highest risk for those who had most recently quit.

Entities:  

Mesh:

Year:  1997        PMID: 9001319     DOI: 10.1164/ajrccm.155.1.9001319

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  176 in total

Review 1.  In search of a cause of cryptogenic fibrosing alveolitis (CFA): one initiating factor or many?

Authors:  M Turner-Warwick
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

Review 2.  Review of cryptogenic fibrosing alveolitis, including current treatment guidelines.

Authors:  S C Bourke; H Clague
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

3.  Toll interacting protein protects bronchial epithelial cells from bleomycin-induced apoptosis.

Authors:  Xiaoyun Li; Sharon E Kim; Ting-Yun Chen; Juan Wang; Xia Yang; Tracy Tabib; Jiangning Tan; Brandon Guo; Sonia Fung; Jing Zhao; John Sembrat; Mauricio Rojas; Sruti Shiva; Robert Lafyatis; Claudette St Croix; Jonathan K Alder; Y Peter Di; Daniel J Kass; Yingze Zhang
Journal:  FASEB J       Date:  2020-06-28       Impact factor: 5.191

Review 4.  Pulmonary fibrosis: thinking outside of the lung.

Authors:  Stavros Garantziotis; Mark P Steele; David A Schwartz
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

Review 5.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Cross regulation between hypoxia-inducible transcription factor-1α (HIF-1α) and transforming growth factor (TGF)-ß1 mediates nickel oxide nanoparticles (NiONPs)-induced pulmonary fibrosis.

Authors:  Fenghua Qian; Mindi He; Weixia Duan; Lin Mao; Qian Li; Zhengping Yu; Zhou Zhou; Yong Zhang
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

Review 7.  Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models.

Authors:  Bosung Shim; Gustavo Pacheco-Rodriguez; Jiro Kato; Thomas N Darling; Martha Vaughan; Joel Moss
Journal:  Eur Respir Rev       Date:  2013-09-01

Review 8.  The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases.

Authors:  Tracy J Doyle; Victor Pinto-Plata; Danielle Morse; Bartolome R Celli; Ivan O Rosas
Journal:  Chest       Date:  2012-10       Impact factor: 9.410

9.  Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts.

Authors:  D W Mapel; W C Hunt; R Utton; K B Baumgartner; J M Samet; D B Coultas
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

10.  Clinical characteristics in patients with asymmetric idiopathic pulmonary fibrosis.

Authors:  Sean J Callahan; Meng Xia; Susan Murray; Kevin R Flaherty
Journal:  Respir Med       Date:  2016-08-31       Impact factor: 3.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.